The March reimbursement list is a reason to be satisfied for hemato-oncology patients. Hematopoietic neoplasms are rare diseases, and pharmacotherapy is the primary method of their treatment. We are glad that the number of reimbursements in hematooncology has increased significantly in recent years. The March reimbursement list is a fulfillment of the long-term expectations of patients with multiple myeloma, who, from March, will have access to treatment: oral lenalidomide in the 1st line in both combinations - with dexamethasone (Rd) and with bortezomib and dexamethasone (RVd), as well as oral pomalidomide in in combination with bortezomib and dexamethasone (PVd) in lines 2 and 4. The March list also included daratumumab in subcutaneous administration, thus making patients independent of the need for many hours of infusion...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
